Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) have been assigned an average recommendation of “Hold” from the twenty-five analysts that are covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $20.16.
A number of research firms have recently issued reports on VRX. TD Securities boosted their price target on shares of Valeant Pharmaceuticals Intl from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 9th. BMO Capital Markets boosted their price objective on shares of Valeant Pharmaceuticals Intl from $17.00 to $20.00 and gave the company a “market perform” rating in a research report on Friday, May 11th. HC Wainwright reaffirmed a “hold” rating and set a $16.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, March 15th. Wells Fargo & Co reaffirmed a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, March 20th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, May 9th.
Shares of VRX stock traded down $0.11 during trading hours on Friday, reaching $21.92. 2,277,401 shares of the stock traded hands, compared to its average volume of 10,426,142. Valeant Pharmaceuticals Intl has a 1-year low of $10.94 and a 1-year high of $24.43. The company has a debt-to-equity ratio of 5.59, a current ratio of 1.18 and a quick ratio of 0.92. The firm has a market capitalization of $7.71 billion, a P/E ratio of 5.72, a P/E/G ratio of 0.44 and a beta of -0.35.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.29. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the previous year, the business earned $1.79 earnings per share. The firm’s revenue was down 5.4% compared to the same quarter last year. sell-side analysts predict that Valeant Pharmaceuticals Intl will post 3.31 EPS for the current fiscal year.
In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De acquired 10,000 shares of the company’s stock in a transaction dated Thursday, March 8th. The stock was bought at an average price of $15.34 per share, for a total transaction of $153,400.00. Following the purchase, the director now owns 106,062 shares in the company, valued at approximately $1,626,991.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Schutter Richard U. De acquired 15,000 shares of the company’s stock in a transaction dated Tuesday, May 15th. The stock was acquired at an average price of $21.83 per share, with a total value of $327,450.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 7,136,629 shares of company stock valued at $110,029,937. Corporate insiders own 11.54% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC raised its stake in shares of Valeant Pharmaceuticals Intl by 122.8% in the 4th quarter. Renaissance Technologies LLC now owns 10,651,189 shares of the specialty pharmaceutical company’s stock valued at $221,332,000 after buying an additional 5,870,689 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Valeant Pharmaceuticals Intl by 9.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 5,696,348 shares of the specialty pharmaceutical company’s stock worth $90,686,000 after purchasing an additional 502,273 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Valeant Pharmaceuticals Intl during the 4th quarter worth about $57,221,000. Fosun International Ltd acquired a new stake in shares of Valeant Pharmaceuticals Intl during the 1st quarter worth about $27,705,000. Finally, Chou Associates Management Inc. increased its position in shares of Valeant Pharmaceuticals Intl by 1,006.8% during the 1st quarter. Chou Associates Management Inc. now owns 1,648,992 shares of the specialty pharmaceutical company’s stock worth $26,252,000 after purchasing an additional 1,500,000 shares in the last quarter. Institutional investors own 50.13% of the company’s stock.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.